论文部分内容阅读
目的观察头孢地尼治疗小儿社区获得性肺炎(CAP)的临床疗效。方法将2013年5月-2015年8月该院儿科门诊收治的CAP患儿289例随机分为4组:Ⅰ组76例、Ⅱ组70例、Ⅲ组70例、Ⅳ组73例,Ⅰ组口服头孢地尼分散片,Ⅱ组口服头孢克肟颗粒,Ⅲ组口服头孢克洛分散片,Ⅳ组口服阿莫西林克拉维酸钾(4∶1)干混悬剂。观察4组临床疗效及不良反应。结果Ⅰ、Ⅱ、Ⅲ、Ⅳ组总有效率分别为92.1%、80.0%、75.7%、80.8%,Ⅰ组总有效率高于Ⅱ、Ⅲ、Ⅳ组,差异均有统计学意义(P<0.05)。Ⅰ、Ⅱ、Ⅲ、Ⅳ组不良反应发生率分别是3.9%、5.7%、7.1%、6.8%,各组间不良反应发生率比较差异均无统计学意义(P>0.05)。结论头孢地尼治疗小儿社区获得性肺炎疗效显著、安全,在临床上有推广应用价值。
Objective To observe the clinical efficacy of cefdinir in children with community-acquired pneumonia (CAP). Methods A total of 28997 cases of CAP in pediatric outpatient department from May 2013 to August 2015 were randomly divided into 4 groups: group Ⅰ 76 cases, group Ⅱ 70 cases, group Ⅲ 70 cases, group Ⅳ 73 cases, group Ⅰ Oral cefdinir dispersible tablets, group Ⅱ oral cefixime particles, group Ⅲ oral cefaclor dispersible tablets, group Ⅳ oral amoxicillin and potassium clavulanate (4: 1) dry suspension. The clinical efficacy and adverse reactions in 4 groups were observed. Results The total effective rates of group Ⅰ, Ⅱ, Ⅲ and Ⅳ were 92.1%, 80.0%, 75.7% and 80.8% respectively. The total effective rate of group Ⅰ was higher than that of group Ⅱ, Ⅲ and Ⅳ (P <0.05 ). The incidence of adverse reactions in group Ⅰ, Ⅱ, Ⅲ and Ⅳ were 3.9%, 5.7%, 7.1% and 6.8%, respectively. There was no significant difference in the incidence of adverse reactions among the groups (P> 0.05). Conclusion Cefdinir treatment of children with community-acquired pneumonia efficacy was significant, safe, and has clinical application value.